Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross‐sectional results of a German multicentre observational study (PROSa)-Reference-Cited by-同舟云学术

Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross‐sectional results of a German multicentre observational study (PROSa)

Published:2021-08-03 Issue:6 Volume:30 Page:
ISSN:0961-5423
Container-title:European Journal of Cancer Care
language:en
Short-container-title:Eur J Cancer Care

Author:

Eichler Martin¹²^ORCID,Pink Daniel³⁴,Menge Franka⁵,Jakob Jens⁶,Hentschel Leopold²,Richter Stephan¹,Hohenberger Peter⁵,Kasper Bernd⁷,Andreou Dimosthenis⁴⁸,Singer Susanne⁹,Grützmann Robert¹⁰,Dmytrow Diana I.¹¹,Arndt Karin¹²,Tuchscherer Armin¹³,Reichardt Peter¹⁴,Ahrens Marit¹⁵,Kunitz Annegret¹⁶,Mohm Johannes¹⁷,Bornhäuser Martin¹²,Schmitt Jochen²¹⁸,Schuler Markus K.¹

Affiliation:

1. Clinic and Polyclinic for Internal Medicine I, University Hospital Carl Gustav Carus Technical University Dresden Dresden Germany

2. National Center for Tumor Diseases (NCT/UCC) Dresden Germany

3. Department of Internal Medicine C University Hospital Greifswald Greifswald Germany

4. Sarcoma Center Berlin‐Brandenburg Helios Hospital Bad Saarow Bad Saarow Germany

5. Division of Surgical Oncology & Thoracic Surgery, Mannheim University Medical Centre University of Heidelberg Mannheim Germany

6. Clinic for General, Visceral, and Pediatric Surgery University Hospital Goettingen Goettingen Germany

7. Interdisciplinary Tumour Centre, Sarcoma Unit University Medical Center Mannheim Mannheim Germany

8. Department of General Orthopedics and Tumor Orthopedics University Hospital Munster Muenster Germany

9. Institute of Medical Biostatistics, Epidemiology and Informatics University Hospital Mainz Mainz Germany

10. Department of Surgery University Hospital Erlangen Erlangen Germany

11. Hospital Frankfurt Hoechst Hoechst Germany

12. German Sarcoma Foundation Woelfersheim Germany

13. Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf University of Cologne Cologne Germany

14. Sarcoma Center Berlin‐Brandenburg Helios Hospital Berlin Buch Berlin Germany

15. Medical Clinic II University Hospital Frankfurt Frankfurt Germany

16. Vivantes Hospital Berlin Germany

17. Onkopraxis, Joint Practice for Hematology and Oncology Dresden Germany

18. Center for Evidence‐Based Healthcare, University Hospital Carl Gustav Carus Technical University Dresden Dresden Germany

Funder

Deutsche Krebshilfe

Publisher

Wiley

Subject

Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ecc.13484

Reference29 articles.

1. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

2. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

3. Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

5. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. KIT-SNAP-tag/cell membrane chromatography model coupled with liquid chromatography–mass spectrometry for anti-GIST compound screening from Evodia rutaecarpa;Analytical and Bioanalytical Chemistry;2024-01-17

2. The psychological impact of sarcoma on affected patients;Psycho-Oncology;2023-11-06

3. Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study;European Journal of Cancer;2023-10

4. Cost Evaluation Analysis of Genetic Testing and Tailored Adjuvant Imatinib in Patients With Resected High-Risk GI Stromal Tumors: The Brazilian Perspective;JCO Global Oncology;2023-09

5. Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System;Cancers;2023-03-20